Immunological approaches to nicotine addiction

Medication Treatments for Nicotine Dependence

Volumn , Issue , 2006, Pages 151-166

  Pentel, Paul ^a   LeSage, Mark ^b   Keyler, Daniel E ^b   Hatsukami, Dorothy ^b  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51749121896     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (52)

1. Pickworth, W.B., Bunker, E.B., and Henningfield, J.E., Transdermal nicotine: reduction of smoking with minimal abuse liability, Psychopharmacology (Berl.), 115(1-2), 9-14, 1994.
2. Benowitz, N.L., Pharmacology of nicotine: addiction and therapeutics, Annu. Rev. Pharmacol. Toxicol., 36, 597-613, 1996.
3. Sellers, E.M., Tyndale, R.F., and Fernandes, L.C., Decreasing smoking behaviour and risk through CYP2A6 inhibition, Drug Discov. Today, 8(11), 487-493, 2003.
4. Benowitz, N.L. et al., Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans, J. Natl. Cancer Inst., 94(2), 108-115, 2002.
5. Malaiyandi, V., Sellers, E.M., and Tyndale, R.F., Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence, Clin. Pharmacol. Ther., 77(3), 145-158, 2005.
6. Hughes, J.R., New treatments for smoking cessation, CA Cancer J. Clin., 50(3), 143-151; quiz, 152-155, 2000.
7. Waters, A.J. et al., Cue-provoked craving and nicotine replacement therapy in smoking cessation, J. Consult. Clin. Psychol., 72(6), 1136-1143, 2004.
8. Perkins, K.A. et al., Tobacco abstinence, smoking cues, and the reinforcing value of smoking, Pharmacol. Biochem. Behav., 47(1), 107-112, 1994.
9. Westman, E.C., Behm, F.M., and Rose, J.E., Airway sensory replacement combined with nicotine replacement for smoking cessation: a randomized, placebo-controlled trial using a citric acid inhaler, Chest, 107, 1358-1364, 1995.
10. Belluzzi, J.D., Wang, R., and Leslie, F.M., Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats, Neuropsychopharmacology, 30(4), 715-712, 2005.
11. Fowler, J.S. et al., Monoamine oxidase and cigarette smoking, Neurotoxicology, 24(1), 75-82, 2003.
12. Herraiz, T. and Chaparro, C., Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors, Biochem. Biophys. Res. Comm., 326(2), 378-386, 2005.
13. U.S. DHHS, The Health Consequences of Smoking-Nicotine Addiction: A Report of the Surgeon General, U.S. Department of Health and Human Services, Washington, D.C., 1988, pp. 374-443.
14. Haney, M. and Kosten, T.R., Therapeutic vaccines for substance dependence, Expert Rev. Vaccines, 3(1), 11-18, 2004.
15. Vocci, F.J. and Chiang, C.N., Vaccines against nicotine: how effective are they likely to be in preventing smoking?, CNS Drugs, 15(7), 505-514, 2001.
16. LeSage, M.G. et al., Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats, Psychopharmacology (Berl.), 184, 409-416, 2006.
17. Carrera, M.R. et al., Investigations using immunization to attenuate the psychoactive effects of nicotine, Bioorg. Med. Chem., 12(3), 563-570, 2004.
18. St. Clair Roberts, J. et al., Longitudinal safety and immunogenicity data of TA-NIC, a novel nicotine vaccine [abstract], in Proc. of the Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA, February 19-22, 2003, Society for Research on Nicotine and Tobacco, Middletown, WI.
19. Meijler, M.M. et al., A new strategy for improved nicotine vaccines using conformationally constrained haptens, J. Am. Chem. Soc., 125(24), 7164-7165, 2003.
20. Sanderson, S.D. et al., Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant, Int. Immunopharmacol., 3(1), 137-146, 2003.
21. Cerny, E.H. et al., Preclinical development of a vaccine against smoking, Onkologie, 25(5), 406-411, 2002.
22. Maurer, P. et al., A therapeutic vaccine for nicotine dependence: preclinical efficacy and phase I safety and immunogenicity, Eur. J. Immunol., 35(7), 2031-2040, 2005.
23. Lindblom, N. et al., Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats, Respiration, 69(3), 254-260, 2002.
24. St. Clair Roberts, J. et al., Safety and immunogenicity of a human nicotine conjugate vaccine, Drug Alcohol Depend., 66, S148, 2002.
25. Hatsukami, D. et al., Safety and immunogenicity of a nicotine conjugate vaccine in current smokers, Clin. Pharmacol. Ther., 78, 456-467, 2005.
26. Pentel, P.R. and Keyler, D.E., Vaccines to treat drug addiction, in New Generation Vaccines, Levine, M.M., Ed., Dekker, New York, 2004, pp. 1057-1066.
27. Hieda, Y. et al., Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain, Int. J. Immunopharmacol., 22(10), 809-819, 2000.
28. Nekhayeva, I.A., Nanovskaya, T.N., Pentci, P.R., Keyler, D.E., Hankins, G.D.V., and Ahmed, M.S., Effects of nioctine-specific antibodies, Nic311 and Nic-IgG, on the transfer of nicotine across the human placenta, Biochem. Pharmacol., 70(11), 1664-1672, 2005.
29. Pentel, P.R. et al., A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats, Pharmacol. Biochem. Behav., 65(1), 191-198, 2000.
30. Satoskar, S.D. et al., Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats, Int. Immunopharmacol., 3(7), 957-970, 2003.
31. Keyler, D.E. et al., Reduced nicotine distribution from mother to fetal brain in rats vaccinated against nicotine: time course and influence of nicotine dosing regimen, Biochem. Pharmacol., 69(9), 1385-1395, 2005.
32. Henningfield, J.E., Miyasato, K., and Jasinski, D.R., Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine, J. Pharmacol. Exp. Ther., 234(1), 1-12, 1985.
33. Keyler, D.E. et al., Altered disposition of repeated nicotine doses in rats immunized against nicotine, Nicotine Tob. Res., 1, 241-249, 1999.
34. Tuncok, Y. et al., Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion, Exp. Clin. Psychopharmacol., 9(2), 228-234, 2001.
35. Kantak, K.M. et al., Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model, Psychopharmacology (Berl.), 148(3), 251-262, 2000.
36. Laurenzana, E.M. et al., Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody, J. Pharmacol. Exp. Ther., 306(3), 1092-1098, 2003.
37. Slotkin, T.A., Fetal nicotine or cocaine exposure: which one is worse?, J. Pharmacol. Exp. Ther., 285(3), 931-945, 1998.
38. Keyler, D.E. et al., Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats, J. Pharmacol. Exp. Ther., 305(2), 587-592, 2003.
39. Malin, D.H. et al., Passive immunization against nicotine attenuates nicotine discrimination, Life Sci., 70, 2793-2798, 2002.
40. Malin, D.H. et al., Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome, Pharmacol. Biochem. Behav., 68(1), 87-92, 2001.
41. Malin, D.H., Passive immunization against nicotine attenuates dependence as measured by mecamylamine-precipitated withdrawal, in Proc. of the Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA, February 20-23, 2002, Society for Research on Nicotine and Tobacco, Middletown, WI.
42. LeSage, M.G. et al., Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations, Psychopharmacology (Berl.), 170(3), 278-286, 2003.
43. Lindmayer, K. et al., Results of a Phase 1, Double Blinded, Controlled Safety and Immunogenicity Trial of NicVAX, a Conjugated Nicotine Vaccine [abstract], paper presented at the Fourth European Conference of the Society for Research on Nicotine and Tobacco, Santander, Spain, 2002.
44. Hatsukami, D. et al., Smokeless tobacco abstinence effects and nicotine gum dose, Psychopharmacology, 106(1), 60-66, 1992.
45. Hieda, Y. et al., Immunization of rats reduces nicotine distribution to brain, Psychopharmacology, 143(2), 150-157, 1999.
46. Kosten, T.R. et al., Phase II Human Study of Cocaine Vaccine TA-CD, paper presented at the College on Problems of Drug Dependence Annual Meeting, Quebec City, June 8-13, 2002.
47. Bonese, K.F. et al., Changes in heroin self-administration by a rhesus monkey after morphine immunization, Nature, 252, 708-710, 1974.
48. Hardin, J.S. et al., A single dose of monoclonal anti-phencyclidine IgG offers longterm reductions in phencyclidine behavioral effects in rats, J. Pharmacol. Exp. Ther., 302(1), 119-126, 2002.
49. McMillan, D.E. et al., Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat, J. Pharmacol. Exp. Ther., 309(3), 1248-1255, 2004.
50. Stratton, K. et al., Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction, National Academy Press, Washington, D.C., 2001.
51. Keyler, D.E. et al., Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose-and affinity-response relationships, Drug Metab. Dispos., 33, 1056-1061, 2005.
52. Fiore, M.C., Bailey, M.C., and Cohen, S.J., Clinical Practice Guideline: Treating Tobacco Use and Dependence: Clinical Practice Guideline, U.S. Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, 2000, p. 175.